COVID-19 Vaccines, Effectiveness, and Immune Responses.
Haneen Imad AbufaresLeen Oyoun AlsoudMohammad A Y AlqudahMohd SharaNelson C SoaresKarem H AlzoubiWaseem El-HuneidiYasser K BustanjiSameh S M SolimanMohammad Harb SemreenPublished in: International journal of molecular sciences (2022)
The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has captivated the globe's attention since its emergence in 2019. This highly infectious, spreadable, and dangerous pathogen has caused health, social, and economic crises. Therefore, a worldwide collaborative effort was made to find an efficient strategy to overcome and develop vaccines. The new vaccines provide an effective immune response that safeguards the community from the virus' severity. WHO has approved nine vaccines for emergency use based on safety and efficacy data collected from various conducted clinical trials. Herein, we review the safety and effectiveness of the WHO-approved COVID-19 vaccines and associated immune responses, and their impact on improving the public's health. Several immunological studies have demonstrated that vaccination dramatically enhances the immune response and reduces the likelihood of future infections in previously infected individuals. However, the type of vaccination and individual health status can significantly affect immune responses. Exposure of healthy individuals to adenovirus vectors or mRNA vaccines causes the early production of antibodies from B and T cells. On the other hand, unhealthy individuals were more likely to experience harmful events due to relapses in their existing conditions. Taken together, aligning with the proper vaccination to a patient's case can result in better outcomes.
Keyphrases
- immune response
- sars cov
- respiratory syndrome coronavirus
- healthcare
- coronavirus disease
- mental health
- public health
- dendritic cells
- clinical trial
- toll like receptor
- randomized controlled trial
- systematic review
- health information
- current status
- social media
- inflammatory response
- machine learning
- type diabetes
- case report
- artificial intelligence
- weight loss
- phase ii
- climate change
- gene therapy
- case control
- phase iii